The Aroon Indicator for SCPH entered a downward trend on November 20, 2023. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 250 similar instances where the Aroon Indicator formed such a pattern. In of the 250 cases the stock moved lower. This puts the odds of a downward move at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 49 cases where SCPH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SCPH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
SCPH broke above its upper Bollinger Band on November 20, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SCPH's RSI Indicator exited the oversold zone, of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on November 20, 2023. You may want to consider a long position or call options on SCPH as a result. In of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for SCPH just turned positive on November 13, 2023. Looking at past instances where SCPH's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SCPH advanced for three days, in of 263 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.108) is normal, around the industry mean (20.498). P/E Ratio (0.000) is within average values for comparable stocks, (137.283). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.811). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (27.548) is also within normal values, averaging (329.636).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. SCPH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SCPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of transformative pharmaceutical products
A.I.dvisor indicates that over the last year, SCPH has been loosely correlated with EDIT. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if SCPH jumps, then EDIT could also see price increases.